CN1 Patterns of Utilization and Implementation Experiences of Oncology Monoclonal Antibodies (MABS) Biosimilars in the U.S.: From BOTH Payers and Healthcare Professionals (HCPS) Perspectives

Biosimilars are highly similar to an originator biologic, with no clinically meaningful differences in safety or efficacy. The adoption of biosimilars might provide an opportunity to lower costs and increase patient access to biologics. The current study sought to understand real-world implementation experiences associated with oncology MAbs biosimilars (trastuzumab, rituximab, and bevacizumab) from both payer and healthcare professional (HCP) perspectives.
Source: Value in Health - Category: International Medicine & Public Health Authors: Tags: Oncology Studies Source Type: research